{"id":"mk-6072","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Gastrointestinal disorders"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Glucokinase activators work by increasing the catalytic activity of glucokinase, an enzyme that acts as a glucose sensor in pancreatic beta cells. By enhancing glucokinase activity, MK-6072 promotes glucose-dependent insulin secretion, thereby improving glycemic control in patients with type 2 diabetes. This mechanism is glucose-dependent, meaning insulin is released primarily when blood glucose is elevated, potentially reducing hypoglycemia risk.","oneSentence":"MK-6072 is a glucokinase activator that enhances glucose sensing and insulin secretion in pancreatic beta cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:21:43.720Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT03182907","phase":"PHASE3","title":"Bezlotoxumab (MK-6072) Versus Placebo in Children With Clostridium Difficile Infection (CDI) (MK-6072-001)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-03-27","conditions":"Clostridium Difficile Infection","enrollment":148},{"nctId":"NCT01241552","phase":"PHASE3","title":"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-10-10","conditions":"Clostridium Difficile Infection","enrollment":1452},{"nctId":"NCT01513239","phase":"PHASE3","title":"A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-02-01","conditions":"Clostridium Difficile Infection","enrollment":1203}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"MK-6072","genericName":"MK-6072","companyName":"Merck Sharp & Dohme LLC","companyId":"merck-sharp-dohme-llc","modality":"Biologic","firstApprovalDate":"","aiSummary":"MK-6072 is a glucokinase activator that enhances glucose sensing and insulin secretion in pancreatic beta cells. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}